Table 2. Cox proportional regression analysis for the prediction of the PCa patients' DFS.
|
Univariate analysis |
Multivariate analysis |
||||
---|---|---|---|---|---|---|
Covariant | HR | 95% CIa | P-valueb | HR | 95% CIa | P-valueb |
miR-145 | ||||||
Positive | 1.00 | 1.00 | ||||
Negative |
2.533 |
1.249–5.137 |
0.010 |
1.264 |
0.489–3.273 |
0.629 |
Gleason score |
2.244 |
1.407–3.578 |
0.001 |
1.660 |
0.944–2.921 |
0.078 |
Clinical stage |
1.504 |
1.178–1.922 |
0.001 |
1.151 |
0.818–1.621 |
0.419 |
PSA |
1.092 |
1.035–1.151 |
0.001 |
1.034 |
0.957–1.117 |
0.397 |
Age |
0.996 |
0.944–1.051 |
0.877 |
0.983 |
0.930–1.039 |
0.548 |
DRE | 2.285 | 1.104–4.727 | 0.026 | 1.535 | 0.679–3.469 | 0.303 |
Abbreviations: CI=confidence interval; DFS=disease-free survival; DRE=digital rectal examination; HR=hazard ratio; PCa=prostate cancer.
CI of the estimated HR.
Test for trend.